A 28-year-old with stage IIB POLE-mutated MSS CRC whose TMB reached 717 mutations/Mb developed severe renal toxicity after off-label adjuvant envafolimab, raising questions about the safety of ICIs in ultra-hypermutated early-stage disease. (AME Case Reports)
Ultra-high TMB POLE-mutated stage II CRC patient develops severe renal toxicity after adjuvant immunotherapy
The CRC Digest